An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus

被引:77
|
作者
Schwartzman, Louis M. [1 ]
Cathcart, Andrea L. [1 ]
Pujanauski, Lindsey M. [1 ]
Qi, Li [1 ]
Kash, John C. [1 ]
Taubenberger, Jeffery K. [1 ]
机构
[1] NIAID, Viral Pathogenesis & Evolut Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA
来源
MBIO | 2015年 / 6卷 / 04期
基金
美国国家卫生研究院;
关键词
IMMUNE-RESPONSES; LETHAL; 1918; HEMAGGLUTININ; NEURAMINIDASE; ANTIBODIES; IMMUNIZATION; CHALLENGE; EVOLUTION; EFFICACY; FERRETS;
D O I
10.1128/mBio.01044-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Influenza virus infections are a global public health problem, with a significant impact of morbidity and mortality from both annual epidemics and pandemics. The current strategy for preventing annual influenza is to develop a new vaccine each year against specific circulating virus strains. Because these vaccines are unlikely to protect against an antigenically divergent strain or a new pandemic virus with a novel hemagglutinin (HA) subtype, there is a critical need for vaccines that protect against all influenza A viruses, a so-called "universal" vaccine. Here we show that mice were broadly protected against challenge with a wide variety of lethal influenza A virus infections (94% aggregate survival following vaccination) with a virus-like particle (VLP) vaccine cocktail. The vaccine consisted of a mixture of VLPs individually displaying H1, H3, H5, or H7 HAs, and vaccinated mice showed significant protection following challenge with influenza viruses expressing 1918 H1, 1957 H2, and avian H5, H6, H7, H10, and H11 hemagglutinin subtypes. These experiments suggest a promising and practical strategy for developing a broadly protective "universal" influenza vaccine. IMPORTANCE The rapid and unpredictable nature of influenza A virus evolution requires new vaccines to be produced annually to match circulating strains. Human infections with influenza viruses derived from animals can cause outbreaks that may be associated with high mortality, and such strains may also adapt to humans to cause a future pandemic. Thus, there is a large public health need to create broadly protective, or "universal," influenza vaccines that could prevent disease from a wide variety of human and animal influenza A viruses. In this study, a noninfectious virus-like particle (VLP) vaccine was shown to offer significant protection against a variety of influenza A viruses in mice, suggesting a practical strategy to develop a universal influenza vaccine.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge
    Carroll, Timothy D.
    Jegaskanda, Sinthujan
    Matzinger, Shannon R.
    Fritts, Linda
    McChesney, Michael B.
    Kent, Stephen J.
    Fairman, Jeffery
    Miller, Christopher J.
    JOURNAL OF INFECTIOUS DISEASES, 2018, 218 (06): : 856 - 867
  • [32] Virus-like Particle Vaccines and Platforms for Vaccine Development
    Kheirvari, Milad
    Liu, Hong
    Tumban, Ebenezer
    VIRUSES-BASEL, 2023, 15 (05):
  • [33] Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
    Hodgins, Breanna
    Pillet, Stephane
    Landry, Nathalie
    Ward, Brian J.
    IMMUNITY & AGEING, 2019, 16 (01)
  • [34] Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice
    Zhang, Li
    Lu, Jing
    Chen, Yin
    Shi, Fengjuan
    Yu, Huiyan
    Huang, Chao
    Cui, Lunbiao
    Shi, Zhiyang
    Jiao, Yongjun
    Hu, Yuemei
    VIRUSES-BASEL, 2015, 7 (08): : 4369 - 4384
  • [35] A Single Intramuscular Dose of a Plant Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response
    Hodgins, Breanna
    Yam, Karen K.
    Winter, Kaitlin
    Pillet, Stephane
    Landry, Nathalie
    Ward, Brian J.
    CLINICAL AND VACCINE IMMUNOLOGY, 2017, 24 (12)
  • [36] Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy
    Lindsay, Brianne J.
    Bonar, Michal M.
    Costas-Cancelas, Ian N.
    Hunt, Kristin
    Makarkov, Alexander I.
    Chierzi, Sabrina
    Krawczyk, Connie M.
    Landry, Nathalie
    Ward, Brian J.
    Rouiller, Isabelle
    VACCINE, 2018, 36 (16) : 2147 - 2154
  • [37] Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles
    Quan, Fu-Shi
    Kim, Yeu-Chun
    Compans, Richard W.
    Prausnitz, Mark R.
    Kang, Sang-Moo
    JOURNAL OF CONTROLLED RELEASE, 2010, 147 (03) : 326 - 332
  • [38] Equine rhinitis A virus-like particle expressing DNA vaccine induces a virus neutralising immune response in mice
    Lynch, Stacey E.
    Gilkerson, James R.
    Symes, Sally J.
    Huang, Jin-an
    Tatarczuch, Liliana
    Hartley, Carol A.
    VIRUS RESEARCH, 2011, 158 (1-2) : 294 - 297
  • [39] Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine
    Wei, Huiling
    Chen, Zhenhai
    Elson, Andrew
    Li, Zhuo
    Abraham, Mathew
    Phan, Shannon
    Kristhnamurthy, Sateesh
    McCray, Paul B., Jr.
    Andrews, Seth
    Stice, Steve
    Sakamoto, Kaori
    Jones, Cheryl
    Tompkins, S. Mark
    He, Biao
    NPJ VACCINES, 2017, 2
  • [40] Bioanalytics for Influenza Virus-Like Particle Characterization and Process Monitoring
    Carvalho, Sofia B.
    Silva, Ricardo J. S.
    Sousa, Marcos F. Q.
    Peixoto, Cristina
    Roldao, Antonio
    Carrondo, Manuel J. T.
    Alves, Paula M.
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, 10